Chuck Ence - 29 Jan 2024 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
CA and CO
Signature
/s/ Chuck Ence
Issuer symbol
RLMD
Transactions as of
29 Jan 2024
Net transactions value
+$150,920
Form type
4
Filing time
31 Jan 2024, 18:28:02 UTC
Previous filing
19 Dec 2023
Next filing
29 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLMD Common Stock Purchase $39,438 +10,800 $3.65 10,800 29 Jan 2024 Direct F1, F2
transaction RLMD Common Stock Purchase $56,053 +14,500 +134% $3.87 25,300 30 Jan 2024 Direct F1, F3
transaction RLMD Common Stock Purchase $55,429 +13,670 +54% $4.05 38,970 31 Jan 2024 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2 Purchase prices range from $3.585 to $3.73 per share, inclusive.
F3 Purchase prices range from $3.755 to $3.99 per share, inclusive.
F4 Purchase prices range from $3.93 to $4.17 per share, inclusive.